Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Deferred Tax Assets (2016)

Guided Therapeutics' Current Deferred Tax Assets history spans 5 years, with the latest figure at $795000.0 for Q4 2016.

  • For Q4 2016, Current Deferred Tax Assets rose 27.0% year-over-year to $795000.0; the TTM value through Dec 2016 reached $795000.0, up 27.0%, while the annual FY2016 figure was $795000.0, 27.0% up from the prior year.
  • Current Deferred Tax Assets for Q4 2016 was $795000.0 at Guided Therapeutics, up from $626000.0 in the prior quarter.
  • Across five years, Current Deferred Tax Assets topped out at $795000.0 in Q4 2016 and bottomed at $277000.0 in Q4 2012.
  • The 5-year median for Current Deferred Tax Assets is $466000.0 (2014), against an average of $490200.0.
  • The largest annual shift saw Current Deferred Tax Assets grew 3.61% in 2013 before it surged 62.37% in 2014.
  • A 5-year view of Current Deferred Tax Assets shows it stood at $277000.0 in 2012, then rose by 3.61% to $287000.0 in 2013, then soared by 62.37% to $466000.0 in 2014, then skyrocketed by 34.33% to $626000.0 in 2015, then grew by 27.0% to $795000.0 in 2016.
  • Per Business Quant, the three most recent readings for GTHP's Current Deferred Tax Assets are $795000.0 (Q4 2016), $626000.0 (Q4 2015), and $466000.0 (Q4 2014).